Study of PM060184 in Patients With Advanced Solid Tumors
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01299636|
Recruitment Status : Completed
First Posted : February 18, 2011
Last Update Posted : November 2, 2015
|Condition or disease||Intervention/treatment||Phase|
|Solid Tumors||Drug: PM060184||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||60 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase I, Multicenter, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM060184 Administered Intravenously to Patients With Advanced Solid Tumors|
|Study Start Date :||January 2011|
|Primary Completion Date :||August 2015|
|Study Completion Date :||August 2015|
PM060184 administered intravenously (i.v.) over 10 minutes at a starting dose of 4 mg/m2/day on three consecutive days q2w (on Days 1-3 and 15-17) every 28 days.
- MTD (maximum tolerated dose) and RD (recommended dose) of PM060184. [ Time Frame: From treatment onset to end of treatment ]To determine the maximum tolerated dose (MTD) and the recommended dose (RD) of PM060184 administered on Days 1 and 8 of a 21-day cycle intravenously (i.v.) over 10 minutes to patients with advanced solid tumors.
- To determine the pharmacokinetics of this drug in patients who have advanced solid tumors. [ Time Frame: Blood samples will be collected up to 48 hours after the first infusion. At the RD, 24-h urine collection samples and 15 additional blood samples up to 48 hours after the second infusion of the first cycle. ]The complete plasma concentration-time profiles of PM06184 will be analyzed by standard non-compartmental methods.The percent of PM060184 total dose excreted unchanged into the urine over the collection interval will be calculated from the urine samples.
- Antitumor activity [ Time Frame: Every six weeks while on treatment. Patients who discontinued treatment without disease progression will be followed every three months until disease progression, other antitumor therapy, death or until the end-of-study date, whichever occurs first. ]Antitumor activity will be measured according to the RECIST (Response Evaluation Criteria In Solid Tumors) version 1.1 or by evaluation of tumor markers
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01299636
|United States, Texas|
|START- South Texas Accelerated Research Therapeutics, LLC|
|San Antonio, Texas, United States, 78229|
|Principal Investigator:||Kyriakos Papadopoulos, MD||START- South Texas Accelerated Research Therapeutics, LLC|